Assessing Changes in Gadoxetate Metabolism by the Liver Using MRI
NCT07541807
Digestive System Diseases, Liver Diseases
Sheffield, United Kingdom
View Trial DetailsNCT Number: NCT02118545
vWF is stored in weibel-palade-bodies of endothelial cells as well as alpha-granula of platelets and is released upon their activation. Endothelial cell dysfunction as well as platelet activation often occur in liver disease and portal hypertension, which may lead to an increase in circulating vWF levels. Indeed, multiple studies have reported that liver disease is associated with increased circulating vWF- antigen (vWF-Ag). Furthermore, increased circulating vWF -Ag Levels have been shown to be associated with increased mortality rates in patients with chronic liver disease. Within a prospective evaluation cohort, the investigators were able to document that patients with increased vWF-Ag levels prior to liver resection suffered from an increased incidence of postoperative liver dysfunction and morbidity. Within this prospective multicenter validation study, the investigators now aim to prospectively validate that circulating vWF-Ag prior to liver resection is a valuable marker to predict postoperative clinical outcome.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Observational
Medical University Vienna, Vienna, State of Vienna, Austria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 90 postoperative days
Preoperative vWF-Ag Predicts Postoperative Liver Dysfunction after Liver Resection
Time frame: 90 postoperative days
Preoperative vWF-Ag Predicts Postoperative Morbidity after Liver Resection
Time frame: 90 postoperative days
Preoperative vWF-Ag Predicts Postoperative Mortality after Liver Resection
Time frame: 90 postoperative days
Preoperative vWF-Ag Predicts Postoperative Hospitalisation after Liver Resection
Medical University of Vienna
Other
Preoperative Von Willebrand Factor to Predict Postoperative Liver Dysfunction and Morbidity After Liver Resection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07541807
Digestive System Diseases, Liver Diseases
Sheffield, United Kingdom
View Trial DetailsNCT04618692
Digestive System Diseases, Digestive System Neoplasms
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06486805
Digestive System Diseases, Liver Diseases
Cairo, Egypt
View Trial DetailsNCT06793007
Digestive System Diseases, Liver Diseases
Kathmandu, Bagmati, Nepal
View Trial Details